Revés, JoanaChapman, Thomas P.Satsangi, JackTorres, Joana2022-05-202022-05-202022Gastroenterology. 2022 Jun;162(7):2120-21220016-5085http://hdl.handle.net/10451/53100© 2022 by the AGA InstituteCurrent treatment algorithms in inflammatory bowel disease (IBD) rely on a “trial and error” approach, and therefore, patients may receive ineffective and costly therapy for many months, with associated risks. Furthermore, after failure of the first biologic, response rates to second-line therapies drop considerably. Personalized medicine, which seeks to identify biomarkers that predict disease course and treatment efficacy, thus remains a significant unmet need in IBD.engjournal article10.1053/j.gastro.2022.03.0281528-0012